PMID: 7523181Sep 1, 1994Paper

In vivo administration of granulocyte colony-stimulating factor promotes neutrophil survival in vitro

European Journal of Haematology
S AdachiY Akiyama

Abstract

We recently showed that recombinant human granulocyte-colony stimulating factor (rhG-CSF) maintained the viability of human neutrophils in incubation for up to 72 hours. However, it is not known whether rhG-CSF can enhance neutrophil survival in in vivo situations. To clarify this issue, we investigated neutrophil survival in vitro following in vivo injection of rhG-CSF. Neutrophils were obtained from 4 pediatric patients with malignancies and healthy adult volunteers before and after rhG-CSF administration. Neutrophils obtained before rhG-CSF treatment started to undergo apoptosis after 24 h of incubation. In contrast, the survival of neutrophils drawn after rhG-CSF administration increased by approximately 24 h. Concomitantly, the appearance of typical ladder-like DNA fragmentation was delayed. Such an increase in neutrophil survival was inhibited by co-incubation with either H 7 (10 mumol/l) or H 8 (20 mumol/l), which worked as protein kinase C inhibitors. Although our study did not measure neutrophil survival in vivo directly, it provides us with further evidence that rhG-CSF may function to prolong neutrophil life expectancy in vivo.

References

Jul 31, 1992·Biochemical and Biophysical Research Communications·Y KannanH Matsuda
Sep 1, 1993·European Journal of Haematology·S Azakami, M Eguchi
Jul 1, 1993·The Journal of Clinical Investigation·M K WhyteC Haslett

❮ Previous
Next ❯

Citations

Feb 13, 2004·The Journal of Veterinary Medical Science·Junichi SanoAtsuhiko Hasegawa
Jan 31, 2008·Journal of Clinical Biochemistry and Nutrition·Eisuke F SatoMasayasu Inoue
Dec 20, 2002·American Journal of Physiology. Cell Physiology·Eisuke F SatoMasayasu Inoue

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.